Latest Breaking News On - General counsel bryant lim - Page 1 : comparemela.com

Two rare disease companies - Idera Pharmaceuticals and Aceragen - are merging to pursue the common goal of an FDA approval that could come as early as 2024.

United statesJohn taylorCarl krausJohn kirbyDaniel salainUs defense threat reduction agencyIdera pharmaceuticalsFast trackQualified infectious disease productThreat reduction agencyChief medical officer carl krausChief operating officer danielGeneral counsel bryant limChief financial officer john kirbyNovaquest the durhamDera bolsters rare disease portfolio with aceragen buyout